US2003017974A1PendingUtilityA1

Fatty acid treatment

46
Priority: Sep 4, 1996Filed: Jun 7, 2002Published: Jan 23, 2003
Est. expirySep 4, 2016(expired)· nominal 20-yr term from priority
Inventors:Catherine A. ScottDavid F. Horrobin
A61P 35/00A61K 31/202A61K 31/201
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.

Claims

exact text as granted — not AI-modified
1 . The use in preparation of a medicament for treating and preventing the side effects of anti-cancer chemotherapy, particularly the side effects caused by any of the drugs listed herein, of a polyunsaturated fatty acid with a carbon chain length of 14 to 26 and with 2 to 6 double bonds in the molecule in cis or trans configuration, and a method of such treatment or prevention wherein said fatty acid is used as an active.  
     
     
         2 . Use or method according to  claim 1  wherein the fatty acid is selected from LA, GLA, DGLA, SA, ALA, EPA and DHA, optionally administered or used with other fatty acids.  
     
     
         3 . Use or method according to  claim 1  wherein the drug is doxorubicin or a related compound which causes cardiotoxicity.  
     
     
         4 . Use or method according to  claim 1  wherein the drug is bleomycin or a related compound which causes lung toxicity.  
     
     
         5 . Use or method according to  claim 1  wherein the drug is cisplatin or a related compound which causes neurotoxicity.  
     
     
         6 . Use or method according to  claim 1  wherein the drug is doxorubicin or a related compound and the fatty acid is LA, GLA or DGLA, optionally administered or used with other fatty acids.  
     
     
         7 . Use or method according to  claim 1  wherein the drug is bleomycin, cyclophosphamide or a related compound and the fatty acid is LA, GLA or DGLA, optionally administered or used with other fatty acids.  
     
     
         8 . Use or method according to  claim 1  wherein the drug is cisplatin or a related compound and the fatty acid is LA, GLA or DGLA, optionally administered or used with other fatty acids.

Join the waitlist — get patent alerts

Track US2003017974A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.